TY - JOUR
T1 - Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic
AU - Agarwal, Shivani
AU - Mathew, Justin
AU - Davis, Georgia M.
AU - Shephardson, Alethea
AU - Levine, Ann
AU - Louard, Rita
AU - Urrutia, Agustina
AU - Perez-Guzman, Citlalli
AU - Umpierrez, Guillermo E.
AU - Peng, Limin
AU - Pasquel, Francisco J.
N1 - Funding Information:
Acknowledgments. The authors greatly appreciate the efforts of their fellow health care workers and support staff at the Montefiore Medical Center for providing outstanding patient care at considerable personal risk on the front lines of this pandemic. The authors express their solidarity with those who are or have been ill with COVID-19 and their families. Funding. S.A. is supported in part by National Institutes of Health (NIH) under award numbers K23DK115896 and P30DK111022. G.M.D. is supported in part by NIH under award number 1K23DK122199-01A1. G.E.U. is partly supported by research grants from the NIH UL1 TR002378 and 1P30DK111024-04. F.J.P. is supported in part by NIH under award numbers 1K23GM128221-03, P30DK11102404, and P30DK111024-05S.
Publisher Copyright:
© 2020 by the American Diabetes Association.
PY - 2021
Y1 - 2021
N2 - OBJECTIVE Real-time continuous glucose monitoring (rtCGM) in critically ill hospitalized patients holds promise; however, real-world data are needed. RESEARCH DESIGN AND METHODS We placed Dexcom G6 CGM on intensive care unit (ICU) patients at Montefiore Medical Center with confirmed coronavirus disease 2019 (COVID-19) infection and glycemic variability. We analyzed inpatient CGM accuracy using point-of-care (POC) glucose–CGM matched pairs and included patients for analysis regardless of clinical status. RESULTS We included 11 patients with CGM: 8 on continuous insulin infusion (CII), 8 on vasopressors, 8 intubated, 4 on high-dose glucocorticoids, 6 on renal replacement therapy, and 2 with anasarca. Accuracy was 12.58% for mean and 6.3% for median absolute relative difference. CGM reduced POC testing by ∼60% for patients on CII. CONCLUSIONS In this real-world preliminary analysis of rtCGM during critical illness, we demonstrate early feasibility, considerable accuracy, and meaningful reduction in the frequency of POC glucose testing.
AB - OBJECTIVE Real-time continuous glucose monitoring (rtCGM) in critically ill hospitalized patients holds promise; however, real-world data are needed. RESEARCH DESIGN AND METHODS We placed Dexcom G6 CGM on intensive care unit (ICU) patients at Montefiore Medical Center with confirmed coronavirus disease 2019 (COVID-19) infection and glycemic variability. We analyzed inpatient CGM accuracy using point-of-care (POC) glucose–CGM matched pairs and included patients for analysis regardless of clinical status. RESULTS We included 11 patients with CGM: 8 on continuous insulin infusion (CII), 8 on vasopressors, 8 intubated, 4 on high-dose glucocorticoids, 6 on renal replacement therapy, and 2 with anasarca. Accuracy was 12.58% for mean and 6.3% for median absolute relative difference. CGM reduced POC testing by ∼60% for patients on CII. CONCLUSIONS In this real-world preliminary analysis of rtCGM during critical illness, we demonstrate early feasibility, considerable accuracy, and meaningful reduction in the frequency of POC glucose testing.
UR - http://www.scopus.com/inward/record.url?scp=85101034742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101034742&partnerID=8YFLogxK
U2 - 10.2337/dc20-2219
DO - 10.2337/dc20-2219
M3 - Article
C2 - 33361145
AN - SCOPUS:85101034742
SN - 0149-5992
VL - 44
SP - 847
EP - 849
JO - Diabetes care
JF - Diabetes care
IS - 3
ER -
